2425 55th Street, Suite 210 Boulder, CO 80301 303-420-4420

Blog

Bolder BioTechnology Announces Positive Preclinical Data for Use of BBT-032 to Inhibit Growth of the SARS-CoV-2 Virus

Boulder, Colorado – August 25, 2020 - Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic. Based upon these…
Read more

Bolder BioTechnology Announces Scientific Presentations at the 2019 Radiation Research Society Annual Meeting

Boulder, Colorado – November 7, 2019 - Bolder BioTechnology is pleased to announce that three scientific presentations describing use of the company’s novel interleukin-11 analog BBT-059 to treat acute radiation syndrome were given at the Radiation Research Society annual meeting held November 3-6, 2019 in San Diego, CA. An invited oral presentation entitled “Pegylated IL-11…
Read more